The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling
Open accessAbstract
The PTH receptor type 1 (PTHR1) mediates the actions of two endogenous polypeptide ligands, PTH and PTHrP, and thereby plays key roles in bone biology. Based on its capacity to stimulate bone formation, the peptide fragment PTH (1–34) is currently in use as therapy for osteoporosis. Abaloparatide (ABL) is a novel synthetic analog of human PTHrP (1–34) that holds promise as a new osteoporosis therapy, as studies in animals suggest that it can stimulate bone formation with less of the accompanying bone resorption and hypercalcemic effects that can occur with PTH (1–34). Recent studies in vitro suggest that certain PTH or PTHrP ligand analogs can distinguish between two high-affinity PTHR1 conformations, R0 and RG, and that efficient binding to R0 results in prolonged signaling responses in cells and prolonged calcemic responses in animals, whereas selective binding to RG results in more transient responses. As intermittent PTH ligand action is known to favor the bone-formation response, whereas continuous ligand action favors the net bone-resorption/calcemic response, we hypothesized that ABL binds more selectively to the RG vs the R0 PTHR1 conformation than does PTH (1–34), and thus induces more transient signaling responses in cells. We show that ABL indeed binds with greater selectivity to the RG conformation than does PTH (1–34), and as a result of this RG bias, ABL mediates more transient cAMP responses in PTHR1-expressing cells. The findings provide a plausible mechanism (ie, transient signaling via RG-selective binding) that can help account for the favorable anabolic effects that ABL has on bone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 720
Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors
Reiter, E., Ahn, S., Shukla, A. K., & Lefkowitz, R. J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105800 · Cited by 583
Sustained cyclic AMP production by parathyroid hormone receptor endocytosis
Ferrandon, S., Feinstein, T. N., Castro, M., Wang, B., Bouley, R., Potts, J. T., Gardella, T. J., & Vilardaga, J.-P. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.206 · Cited by 572
Self-citationGesty-Palmer, D., Chen, M., Reiter, E., Ahn, S., Nelson, C. D., Wang, S., Eckhardt, A. E., Cowan, C. L., Spurney, R. F., Luttrell, L. M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513380200 · Cited by 476
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Baron, R., & Hesse, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2332 · Cited by 320
Recent developments in biased agonism
Wisler, J. W., Xiao, K., Thomsen, A. R., & Lefkowitz, R. J. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.10.008 · Cited by 287
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O'Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 287
Leder, B. Z., O'Dea, L. S. L., Zanchetta, J. R., Kumar, P., Banks, K., McKay, K., Lyttle, C. R., & Hattersley, G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3718 · Cited by 261
Self-citationRetromer terminates the generation of cAMP by internalized PTH receptors
Feinstein, T. N., Wehbi, V. L., Ardura, J. A., Wheeler, D. S., Ferrandon, S., Gardella, T. J., & Vilardaga, J.-P. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.545 · Cited by 236
Self-citationDean, T., Vilardaga, J.-P., Potts, J. T., & Gardella, T. J. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0274 · Cited by 227
Self-citationGesty-Palmer, D., Flannery, P., Yuan, L., Corsino, L., Spurney, R., Lefkowitz, R. J., & Luttrell, L. M. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000071 · Cited by 205
Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm
Vilardaga, J., Romero, G. G., Friedman, P. A., & Gardella, T. J. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0465-9 · Cited by 148
Self-citationPioszak, A. A., Parker, N. R., Gardella, T. J., & Xu, H. E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022905 · Cited by 147
Self-citationA Luminescent Biosensor with Increased Dynamic Range for Intracellular cAMP
Binkowski, B. F., Butler, B. L., Stecha, P., Eggers, C. T., Otto, P., Zimmerman, K., Vidugiris, G. J. A., Wood, M. G., Encell, L. P., Fan, F., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb200248h · Cited by 141
Minireview: More Than Just a Hammer: Ligand “Bias” and Pharmaceutical Discovery
Luttrell, L. M. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1314 · Cited by 136
Endosomal GPCR signaling turned off by negative feedback actions of PKA and v-ATPase
Gidon, A., Al‐bataineh, M. M., Jean‐Alphonse, F., Stevenson, H. P., Watanabe, T., Louet, C., Khatri, A., Calero, G. A., Pastor‐Soler, N. M., Gardella, T. J., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1589 · Cited by 98
Self-citationMaeda, A., Okazaki, M., Baron, D. M., Dean, T., Khatri, A., Mahon, M. J., Segawa, H., Abou‐Samra, A., Jüppner, H., Bloch, K. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301674110 · Cited by 87
Self-citationDean, T., Linglart, A., Mahon, M. J., Bastepe, M., Jüppner, H., Potts, J. T. J., & Gardella, T. J. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0349 · Cited by 71
Self-citationCupp, M. E., Nayak, S. K., Adem, A. S., & Thomsen, W. J. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.199752 · Cited by 70
Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?
Hothersall, J. D., Brown, A., Dale, I. L., & Rawlins, P. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.015 · Cited by 69
Non-canonical signaling of the PTH receptor
Vilardaga, J., Gardella, T. J., Wehbi, V. L., & Feinstein, T. N. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.05.004 · Cited by 67
Self-citationRey, A., Manen, D., Rizzoli, R., Caverzasio, J., & Ferrari, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606762200 · Cited by 43
Hoare, S. R. J., Sullivan, S. K., Pahuja, A., LING, N. C., Crowe, P. D., & Grigoriadis, D. E. (2003) · Peptides · doi:10.1016/j.peptides.2003.09.002 · Cited by 29
Cited by
Osteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Miller, P. D., Hattersley, G., Riis, B. J., Williams, G. C., Lau, E., Russo, L. A., Alexandersen, P., Zerbini, C. A. F., Hu, M.-Y., Harris, A. G., et al. (2016) · JAMA · doi:10.1001/jama.2016.11136 · Cited by 875
Self-citationMolecular Mechanisms and Emerging Therapeutics for Osteoporosis
Noh, J.-Y., Yang, Y., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207623 · Cited by 287
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
PTH receptor-1 signalling—mechanistic insights and therapeutic prospects
Cheloha, R. W., Gellman, S. H., Vilardaga, J.-P., & Gardella, T. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.139 · Cited by 265
Self-citation
Metadata
- Authors
- Hattersley, G., Dean, T., Corbin, B. A., Bahar, H., & Gardella, T. J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2016-01-01
- Volume
- 157
- Issue
- 1
- Pages
- 141-149
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2176994106
- Cited by
- 300
- References
- 23
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.